TQB3909

TQB3909 is an orally bioavailable small molecule inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2). By binding to and inhibiting Bcl-2, TQB3909 restores caspase-mediated apoptosis in tumor cells. This leads to the release of pro-apoptotic proteins such as BAK, BAX, and BAD; promotes cytochrome c release from mitochondria; stimulates caspase 3/7 activity and cleavage of caspase 3/9; and induces apoptosis. The drug is being developed primarily for hematologic malignancies (such as chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle-cell lymphoma, myelofibrosis) and solid tumors including breast cancer. It is currently in phase I/II clinical trials. The developer is Chia Tai Tianqing Pharmaceutical Group[1][2][3][4][5][6][7].

Other names

Bcl-2 inhibitor TQB3909Bcl2 inhibitor TQB3909Bcl 2 inhibitor TQB3909